The transmembrane cell adhesion receptor α V β 3 integrin (α V β 3 ) has been identified as an important molecular target for cancer imaging and therapy. We have developed a tetrameric cyclic RGD (Arg-Gly-Asp) peptide-based radiotracer 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 , which successfully captured α V β 3 -positive tumors and angiogenesis by positron emission tomography. Here, we subsequently evaluated its therapeutic potential and side effects using 
Introduction
Molecular targeted radionuclide therapy (MTRT), which is a promising cancer treatment option, is performed by the systemic administration of a specific molecular vehicle, i.e., antibody, peptide or small organic molecule that is radiolabeled with a cytocidal energy-releasing radionuclide (α-or β − -particle emitter or Auger electron emitter) to elicit a therapeutic effect on the targeted tumoral lesions (1) (2) (3) (4) . The key advantages such as rapid blood clearance, tissue penetration capability, low immunogenicity, and relatively easy and cost-effective production, have made the peptide-based MTRT more attractive as a treatment strategy with clinical translational potential (4) (5) (6) .
MTRT with radiolabeled somatostatin analogs (peptide ligands), targeting somatostatin receptor-highly expressed neuroendocrine tumors, have been used in clinical practice with convincing therapeutic efficacy (6, 7) . Of the candidate target molecules for MTRT, α V β 3 integrin (α V β 3 ) is a promising one (4, 5) . It is a transmembrane glycoprotein receptor and an important cell adhesion molecule that plays important roles in tumor growth, invasion, metastasis, and angiogenesis. It is highly expressed on various types of tumor cells and activated endothelial cells during angiogenesis (8) (9) (10) . The α V β 3 has been identified as a biomarker for tumor angiogenesis (a key event required for tumor growth), which makes it more attractive as a therapeutic target (11) (12) (13) (14) . Of equal importance is the well-established key structure of the cyclic pentapeptide containing a tripeptide sequence Arg-Gly-Asp 7 (cRGD) with high specificity and affinity for the α V β 3 (15) . A series of cRGD-based radiotracers have been designed, synthesized, and evaluated in in vitro and in vivo studies (5, 16, 17) . Of those some early developed ones have been in clinical trials, showing valuable results for cancer imaging (17) . Meanwhile, some research groups have begun to explore the therapeutic efficiency of cRGD ligand-α V β 3 receptor based MTRT (18) (19) (20) (21) (22) (23) .
We have developed a tetrameric cRGD peptide-based radiopharmaceutical 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 containing 4 copies of a cRGD monomer grafted onto one side of a cyclic decapeptide scaffold named RAFT (Regioselectively Addressable Functionalized Template) and a copper chelator 1,4,8,11-tetraazacyclotetradecane (cyclam) on the other side of the RAFT (24, 25) . This radiocompound possesses a greatly improved α V β 3 -binding specificity and affinity as well as a high internalization capability due to the multimeric presentation of cRGD motifs (25) (26) (27) , and is capable of being applied for both imaging and therapy because of the suitable half-life (12.7 h) of copper-64 ( 64 Cu) with multiple decay modes-β + (17.8%) used for positron emission tomography (PET), β − (38.4%) and Auger electron (43%) used for therapeutic radiation (28) . In fact, the antitumor activities of 64 Cu have been reported in preclinical studies using 64 Cu-labeled antibody or peptide (somatostatin analog), or the hypoxia radiotracer 64 Cu-ATSM (29) (30) (31) (32) . Our previous studies have demonstrated the favorable biopharmacokinetics of and predominant renal excretion, and revealed the positive correlation between tumor uptake of this probe and the corresponding tumoral α V β 3 expression levels (25, 33) . PET imaging showed the potential of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 for visualizing tumor angiogenesis and monitoring anti-angiogenic therapy (34) . Importantly, the retention of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 in kidneys (principal dose-limiting organ for peptide-based MTRT) could be significantly reduced by co-injection with renoprotective agents, the gelatin-containing solution Gelofusine (GF) and the basic amino acid L-lysine (Lys) (33, 35) .
The present study subsequently aimed to evaluate the therapeutic potential and side effects of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 in an α V β 3 -positive tumor mouse model.
Materials and Methods

Peptides and radiolabeling
Cyclam-RAFT-c(-RGDfK-) 4 ( Fig.  1A ) and chelator-unconjugated RAFT-c(-RGDfK-) 4 (molecular weight: 4,119.6, and 3,879.3, respectively) were synthesized as previously reported (24) . 64 Cu was produced using a cyclotron at the National Institute of Radiological Sciences (NIRS, Chiba, Japan). 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 was prepared with a specific activity of 37 MBq/nmole and a radiochemical purity of >99.5%, based on our published procedures (25, 33, 34) .
Animal tumor model and α V β 3 expression
Animal procedures were approved by the Institutional Animal Care and Use Committee of NIRS. BALB/cAJcl-nu/nu mice (5-week-old female, CLEA Japan, Inc.) were injected subcutaneously in the right flank with 5 × 10 6 U87MG human glioblastoma cells (25, 33) 17−20 days before the experiments. Tumor mass was measured with a digital caliper. Tumor volume (mm 3 ) was determined using the formula 0.5 × length × width 2 , and the fold of change was calculated by dividing the obtained value by the initial tumor volume measured before treatment (day 0). The survival endpoint of tumor-bearing mice was determined when tumor volume exceeded 1,500 mm 3 .
The α V β 3 expression in U87MG tumor cells that were used for the present study was validated in both cell culture and xenograft levels, based on our published procedures (25) Tumor-bearing mice (n = 6/each group) were injected (via the tail vein) with 0.185 MBq (0.005 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 formulated in normal saline (NS) or NS with 1% Tween 80 (NS/Tw80). At 3 h post-injection (p.i.), the mice were sacrificed, and blood was drawn by cardiac puncture. Tumor, muscle, liver, and kidney were dissected and weighed, and radioactivity was measured using a gamma counter with decay correction.
Tumor and organ uptake were presented as the percentage of injected radioactivity per gram of tissue (%ID/g) normalized to 20 g body weight.
Similar assays were performed in tumor-bearing mice (n = 5/each group) that received 0.74 MBq (0.02 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 formulated in NS/Tw80 or NS/Tw80 supplemented with Gelofusine (GF, 80 mg/kg; Braun Medical) and L-lysine (Lys, 400 mg/kg; Sigma-Aldrich) (NS/Tw80/GF/Lys) (33) . GF, consisting of a 40 g/L solution of succinylated gelatin, was a kind gift from Lucie Sancey (University of Lyon 1, France).
Experiment 2: Effects of peptide doses
Tumor-bearing mice (n = 4−5) were injected with 0.74 MBq of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 in NS/Tw80/GF/Lys injection vehicle added with varying amounts of unlabeled cyclam-RAFT-c(-RGDfK-) 4 to give final injectates at ascending doses of 0.25, 0.5, 1, 2, 4, and 10 nmole. The effects of peptide doses on the tumor and organ tracer uptake were evaluated at 3 h p.i.
Experiment 3: Chronological changes at therapeutic doses
The biodistribution data of 74 MBq (2 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 was obtained from tumor-bearing mice (n = 5−6) that were injected with 0.74 MBq of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 in NS/Tw80/GF/Lys injection vehicle, with the peptide dose 
Therapy experiments
Four groups of tumor-bearing mice (n = 6−8) were injected with NS/Tw80 (vehicle control), 1 nmole of RAFT-c(-RGDfK-) 4 (peptide control), or 37 MBq (1 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 with or without GF/Lys (± GF/Lys). In the second set of therapy study, 4 groups of tumor-bearing mice (n = 9−10) received NS/Tw80/GF/Lys (vehicle 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 . Following injections, mouse body weight (g) and tumor size were measured every 2 days, and survival endpoint days were recorded.
Hematology and hepatorenal functions
For all groups of mice involved in the therapy experiments, routine peripheral blood tests were performed at days 3, 7, and 12 p.i. as well as on their survival endpoint days, while the routine hepatorenal function test was performed only on the survival endpoint day due to the limitation of blood collection. For detailed procedures, see Supplementary information.
Side effects were also studied in 2 groups of tumor-free mice (n = 4/each group, at the same age as the tumor-bearing mice used for the therapy study) that received administration of NS/Tw80/GF/Lys vehicle and 74 MBq of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 , respectively. The survival endpoint was determined based on the mean survival day of 74-MBq-treated tumor-bearing mice.
Autoradiography and histological studies
Tumor-bearing mice were injected with the therapeutic dose of 74 MBq (2 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 , and sacrificed at 3 h p.i. 
Statistical analysis
Quantitative data were presented as mean ± standard deviation (SD). Unpaired t-test was used for 2 groups' comparison, and one-way ANOVA followed by Dunnett test for multiple comparisons (KaleidaGraph Version 4.0, Synergy Software). Based on the period from day 0 p.i. to the specified survival endpoint day, Kaplan-Meier survival curves were plotted using KaleidaGraph, and the mean survival days were compared. P values < 0.05 were considered statistically significant. 
Effects of injection vehicles on 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 biodistribution
Cyclam-RAFT-c(-RGDfK-) 4 with low water solubility was dissolved in dimethyl sulfoxide and labeled with 64 Cu. Previously, 64 Cu-labeled cyclam-RAFT-c(-RGDfK-) 4 diluted in NS just before in vivo use. Based on the results of solubility test conducted earlier (unpublished work), in the present study, Tw80 (a pharmaceutical excipient) was added to the injectate for solubility improvement. As shown in Figure 2A , the addition of 1% Tw80 to the NS-vehicle led to a markedly increased tumor uptake from 3.4 ± 0.61% ID/g to 10.8 ± 0.86% ID/g at 3 h p.i. Moreover, the tumor-to-blood ratio was significantly higher with NS/Tw80-vehicle than with NS-vehicle (158 ± 37 vs. 102 ± 38, P = 0.025). The tumor-to-muscle ratio with NS/Tw80-vehicle was slightly higher than that with NS-vehicle (18.8 ± 2.5 vs. 16.7 ± 4.4, P > 0.05). However, the kidney uptake was unfavorably elevated with the use of NS/Tw80-vehicle ( Fig. 2A) . With the addition of GF and Lys, which were previously reported to markedly reduce the renal uptake and slightly increase the tumor uptake of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 (33) , the high renal uptake caused by NS/Tw80 was greatly reduced by 54%, while no significant difference was found with the tumor uptake values (Fig. 2B) .
Radiotherapy with 64 Cu-cyclam-RAFT-c(-RGDfK-) 4
The treatment outcomes of mice that received single administration of 37 MBq (1 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 ± GF/Lys are shown in Supplementary Figure S1 , Table S1 , and Table S2 . 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 Tables S1 and S2 ). Based on these results, 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 formulated in the vehicle of NS/Tw80/GF/Lys was used for all subsequent studies.
The treatment outcomes of mice that received single administration of increasing dose of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 are summarized in Figure 3 , Table 1, and   Supplementary Table S3 . No significant difference was found in the initial tumor volumes
(mean values ranging from 89 to 96 mm 3 ) among the 4 groups of mice. The administration of 2 nmole of RAFT-c(-RGDfK-) 4 did not significantly influence the tumor growth as compared to the vehicle control (Fig. 3A) . As compared to 37 MBq (1 nmole), the treatment with 74
MBq (2 nmole) of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 resulted in an improved tumor growth inhibition (Fig. 3A) ; at day 12 p.i., the fold change in tumor volume was 4.96 ± 2.79 (P = 0.011) and 6.96 ± 2.73 (P = 0.236) for 74-MBq-and 37-MBq-treated mice, respectively, vs. control, P = 0.013) (Fig. 3B ). All groups of mice showed similar body weight gains with no significant difference (Fig. 3C) . Significantly decreased white blood cell count (WBC) was found in 74-MBq-and 37-MBq-treated mice on days 7 and 12 ( Fig. 3D and Supplementary   Table S3 ). Except for this, the red blood cell count (RBC) (Fig. 3E) , the platelet count (PLT) (Fig. 3F) , and the measurements of hemoglobin, hematocrits and red blood cell indices (data not shown) did not indicate hematological toxicity. The results of hepatorenal functions (Table   1) showed slightly elevated levels of creatinine (CRE) and gamma-glutamyl transpeptidase (GGT) in 74-MBq-treated mice on their survival endpoints.
Supplementary Figure S2 and Table S4 show the results of toxicity studies performed in tumor-free mice. As compared to the vehicle control, 74 MBq of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 induced a 26.5% decrease in WBC (2300 ± 410/μL vs.
3130 ± 460/μL; P = 0.037) and a 21.8% increase in PLT (59.5 ± 4.1 ×10 4 /μL vs. 72.5 ± 8.8 ×10 4 /μL; P = 0.036) at day 3 p.i., both of which then recovered to the control levels by day 7 p.i. Except for these, no other significant alterations were detected.
Autoradiography and histological studies
Autoradiographic examination (Fig. 4A) indicates a relatively heterogeneous intratumoral distribution of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 . HE staining (Fig. 4B) did not show obvious necrosis in the examined tumor. Figure 4C depicts 
on tumor cells, which was overlapped with the radioactive distribution (Fig. 4A ). CD31 staining (Fig. 4D) showed that the tumor microvasculature was quite homogeneous with high capillary density. The findings of HE-and CD31-staining may exclude the relation of the relatively weak radioactivity accumulation with the necrosis and poor blood supply.
The results of time course of histological analysis of the 74-MBq-treated tumors are presented in Figure 5 . Ki67 staining revealed a significantly reduced proliferation index (the percentage of Ki67-positive cells) at day 1 p.i. for treated tumors as compared to the vehicle control, which tended to maintain at least until day 6 (Fig. 5B) . For MVD as determined by CD31 staining, a significant decrease was found at the later time point of day 6 in treated tumors as compare to the control (Fig. 5C ). TUNEL staining detected generally low levels of apoptosis for both treated and vehicle control tumors at all time points (days 1, 3, and 6), but it was also found that at day 6 the DNA fragmentation and apoptosis seemed to slightly increase in treated tumors (Fig. 5A , right panels). 
Biodistribution and radiation dosimetry studies
for 1, 2, 4, and 10 nmole, respectively). Except for the kidney, similar dose-responses were observed in other normal tissues examined. The highest uptake was found in kidney, followed by liver and tumor. As compared to liver, the tracer uptake by the α V β 3 -positive tumor was more affected. A 40-fold increase of peptide dose from 0.25 to 10 nmole induced 83.5% reduction in the tumor uptake vs. 52.1% reduction in the liver uptake.
Time course of 0.74 MBq of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 biodistribution is presented in Figure 6B , which most likely represents the biopharmacokinetics of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 when used for 74 MBq-radiotherapy because the same peptide dose of 2 nmole was utilized. This radiopharmaceutical had rapid blood clearance, rapid and high tumor uptake, and predominant renal excretion. The tumor uptake was 3.8 ± 0.39% ID/g at 1 h p.i., which was maintained at 3.4 ± 0.58% ID/g at 24 h p.i. Table 2 radiosensitivity, activity distribution, and so on, should be considered (29, 38) . In a rat therapy study using 64 Cu-labeled peptide analog of somatostatin, the estimated TADs between 4.7−5.4
Gy were reported to give significant tumor growth inhibition (30) . As for the therapy studies using 177 Lu or 90 Y-labeled cRGD peptides in similar U87MG tumor models, no TAD was reported (22, 23) . The present study showed mean TADs of 1.28 Gy (34.6 mGy/MBq) and and 86.6 ± 23 μmol/L obtained with similar therapeutics using 37 MBq of 177 Lu-and 90 Y-labeled analogs, respectively (23).
As mentioned, the therapeutic doses of 37 and 74 MBq contained 1 and 2 
nmole of cyclam-RAFT-c(-RGDfK-) 4 , respectively, which are however not yet the most optimal dosing because the peptide dose escalation studies (Fig. 6A, 0 .25−10 nmole; Supplementary Fig. S5, 0 .005−0.5 and 10 nmole) revealed significantly reduced tumor uptake at such doses, most likely due to saturation of the α V β 3 receptor. The saturable peptide uptake was also reported by other investigators (19, 42) . We found that increasing the administered activity of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 from 37 to 74 MBq led to only a 1.41-fold higher TAD and somewhat enhanced antitumor effects. Approaches for avoiding saturation-caused decrease of tumor uptake would lead to an improved therapeutic efficacy of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 . One way is to enhance the specific activity of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4, which would be achieved by improving the specific radioactivity and purity of 64 CuCl 2 produced, optimizing the labeling and purification protocols, and/or modifying the peptide itself. Another possible strategy is to perform rapid 
Human dosimetry was extrapolated from the biodistribution data of 64 Cu-cyclam-RAFT-c(-RGDfK-) 4 (+ GF/Lys) in tumor-bearing mice (see details in Supplementary Table S5 ). The mean whole body effective dose of 0.030 mSV/MBq is similar to 0.031 mSV/MBq (estimated from rat data) for 177 67 Cu-radiocompounds are considered more appropriate for the treatment of small tumors ≤5 mm in diameter (44, 45) . We have confirmed the radiolabeling of cyclam-RAFT-c(-RGDfK-) 4 with 67 Cu using the same procedure for preparing 67 Cu-cyclam-RAFT-c(-RGDfK-) 4 for future therapy study.
In conclusion, this study provides the first evaluation of the potential of 64 
